Testing two (of several) intravenous iron dosing strategies in hemodialysis

Margaret K. Yu, Glenn M. Chertow


Worldwide, over 2.6 million persons receive treatment for end-stage kidney disease (ESKD) and this number is expected to double by 2030 (1). Nearly all patients with ESKD develop anemia and the current standard of care is to treat with a combination of erythropoiesis-stimulating agents (ESAs) and intravenous (IV) iron (2). Patients on dialysis, and particularly those on hemodialysis, tend to have relatively low iron stores due to low dietary intake, poor gastrointestinal absorption of iron, and blood loss from hemodialysis, lab draws, vascular access procedures, and gastrointestinal hemorrhage.